Kwality Pharmaceuticals L
₹3,643.30
+3.75%
Delayed · cached 15 min
Fair value analysis
KPL
Kwality Pharmaceuticals L
₹3,511.60
Close used for this calculation
₹1,801.58Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
47/100
Quality radar
Consensus fair value
₹1,801.58
Above FV▼ -48.7% against the close used
Model range ₹739.04 – ₹2,317.29
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₹739.04Fair value₹1,801.58Bull₹2,317.29
FairClose
52-week traded range
52W low ₹3,267.1052W high ₹3,661.40
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
Kwality Pharmaceuticals L closed at ₹3,511.60, 94.9% above the consensus fair value of ₹1,801.58 drawn from 8 valuation models.
Financial DNA score 47/100 — Average. P/E of 46.3x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₹1,288.40
-63.3%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₹739.04
-79.0%
√(22.5 × EPS × BVPS)
EPS=64.91, BVPS=373.97 · outside Graham range (P/E 46.3, P/B 9.4) — asset-light, treat as a rough floor
P/E Fair Value
₹2,317.29
-34.0%
EPS × 35.7x (sector P/E)
EPS=64.91, Sector P/E=35.7x
Peter Lynch (PEG)
₹1,622.75
-53.8%
EPS × Growth% (PEG = 1 is fair)
EPS=64.91, g=25%
EV/EBITDA
₹2,186.85
-37.7%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=1.38B
Book Value (P/B)
₹1,551.99
-55.8%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=373.97, ROE=22.6%, g=6%, r=10%
Reverse DCF
₹3,511.60
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 20.6% | Historical: 25%
Margin of Safety
₹1,086.18
-69.1%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=1448.24, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.